Skip to main content
. Author manuscript; available in PMC: 2020 Feb 24.
Published in final edited form as: Diabetes Obes Metab. 2017 Aug 8;20(1):129–140. doi: 10.1111/dom.13049

Figure 1.

Figure 1.

Weighted Kaplan-Meier Curves Identifying those Remaining without Bladder Cancer over Follow-up among Initiators of Pioglitazone (dotted line) or Active Comparator (solid line; Dipeptidyl-peptidase-4 or Sulfonylureas) with at Least 180 days of Follow-up.